S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

Blueprint Medicines News Headlines (NASDAQ:BPMC)

$59.26
-2.71 (-4.37 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$58.56
Now: $59.26
$63.36
50-Day Range
$61.50
MA: $69.92
$82.22
52-Week Range
$58.56
Now: $59.26
$102.98
Volume825,700 shs
Average Volume902,049 shs
Market Capitalization$3.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Headlines

Blueprint Medicines (NASDAQ BPMC) News Headlines

Source:
DateHeadline
Blueprint MedicinesBlueprint Medicines
www.fool.com - February 22 at 11:38 PM
Blueprint Medicines to Present at Upcoming Investor ConferencesBlueprint Medicines to Present at Upcoming Investor Conferences
finance.yahoo.com - February 19 at 8:21 AM
Ipsen writes down $725M after largest-ever acquisition, trial woesIpsen writes down $725M after largest-ever acquisition, trial woes
finance.yahoo.com - February 18 at 1:35 PM
Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $103.00Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $103.00
www.americanbankingnews.com - February 18 at 10:06 AM
Svb Leerink Weighs in on Blueprint Medicines Corps Q2 2020 Earnings (NASDAQ:BPMC)Svb Leerink Weighs in on Blueprint Medicines Corp's Q2 2020 Earnings (NASDAQ:BPMC)
www.americanbankingnews.com - February 17 at 2:40 AM
Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top MarkBlueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark
finance.yahoo.com - February 14 at 2:58 PM
Edited Transcript of BPMC earnings conference call or presentation 13-Feb-20 1:30pm GMTEdited Transcript of BPMC earnings conference call or presentation 13-Feb-20 1:30pm GMT
finance.yahoo.com - February 14 at 8:32 AM
Blueprint Medicines (NASDAQ:BPMC) Releases Quarterly  Earnings Results, Beats Expectations By $0.36 EPSBlueprint Medicines (NASDAQ:BPMC) Releases Quarterly Earnings Results, Beats Expectations By $0.36 EPS
www.americanbankingnews.com - February 13 at 9:08 PM
Blueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from CowenBlueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - February 13 at 4:35 PM
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue EstimatesBlueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
www.nasdaq.com - February 13 at 1:42 PM
Blueprint Medicines Corporation (BPMC)Blueprint Medicines Corporation (BPMC)
finance.yahoo.com - February 13 at 8:41 AM
Blueprint Medicines EPS beats by $0.41, beats on revenueBlueprint Medicines EPS beats by $0.41, beats on revenue
seekingalpha.com - February 13 at 8:41 AM
Blueprint Medicines Q4 Earnings PreviewBlueprint Medicines Q4 Earnings Preview
seekingalpha.com - February 12 at 11:45 PM
Stock To Watch: Blueprint Medicines (BPMC)Stock To Watch: Blueprint Medicines (BPMC)
www.nasdaq.com - February 12 at 1:44 PM
Blueprint Medicines Corp (NASDAQ:BPMC) Expected to Announce Quarterly Sales of $24.02 MillionBlueprint Medicines Corp (NASDAQ:BPMC) Expected to Announce Quarterly Sales of $24.02 Million
www.americanbankingnews.com - February 12 at 3:54 AM
 Brokerages Anticipate Blueprint Medicines Corp (NASDAQ:BPMC) Will Post Earnings of -$1.71 Per Share Brokerages Anticipate Blueprint Medicines Corp (NASDAQ:BPMC) Will Post Earnings of -$1.71 Per Share
www.americanbankingnews.com - February 10 at 4:14 AM
Blueprint Medicines NDA for Avapritinib Gets Extended ReviewBlueprint Medicines' NDA for Avapritinib Gets Extended Review
finance.yahoo.com - February 7 at 4:52 PM
Blueprint Medicines Most Recent Raise Is A Necessary DesperationBlueprint Medicine's Most Recent Raise Is A Necessary Desperation
seekingalpha.com - February 7 at 11:52 AM
Blueprint Medicines (BPMC) Set to Announce Earnings on ThursdayBlueprint Medicines (BPMC) Set to Announce Earnings on Thursday
www.americanbankingnews.com - February 7 at 10:36 AM
FDA extends action date for Blueprints avapritinibFDA extends action date for Blueprint's avapritinib
seekingalpha.com - February 6 at 5:31 PM
Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal TumorBlueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
finance.yahoo.com - February 6 at 12:30 PM
Blueprint Medicines Corp (NASDAQ:BPMC) Receives Consensus Recommendation of "Buy" from AnalystsBlueprint Medicines Corp (NASDAQ:BPMC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 1 at 5:31 AM
Blueprint Medicines Enters Oversold Territory (BPMC)Blueprint Medicines Enters Oversold Territory (BPMC)
www.nasdaq.com - January 24 at 5:45 PM
Blueprint Medicines Announces Proposed Public Offering of Shares of Common StockBlueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
finance.yahoo.com - January 21 at 9:02 PM
Blueprint Secures Favorable FDA Approval For PDGFRA Exon 18 Mutant GISTBlueprint Secures Favorable FDA Approval For PDGFRA Exon 18 Mutant GIST
seekingalpha.com - January 17 at 7:21 AM
Heres Why Were Not Too Worried About Blueprint Mediciness (NASDAQ:BPMC) Cash Burn SituationHere's Why We're Not Too Worried About Blueprint Medicines's (NASDAQ:BPMC) Cash Burn Situation
finance.yahoo.com - January 16 at 7:33 PM
Here's Why We're Not Too Worried About Blueprint Medicines's (NASDAQ:BPMC) Cash Burn SituationHere's Why We're Not Too Worried About Blueprint Medicines's (NASDAQ:BPMC) Cash Burn Situation
finance.yahoo.com - January 16 at 9:32 AM
Blueprint Medicines lays out growth plansBlueprint Medicines lays out growth plans
seekingalpha.com - January 13 at 5:37 PM
Blueprint Medicines Announces 2020 Corporate GoalsBlueprint Medicines Announces 2020 Corporate Goals
finance.yahoo.com - January 13 at 5:37 PM
Blueprint prices new cancer drug at $32,000 per monthBlueprint prices new cancer drug at $32,000 per month
www.marketwatch.com - January 10 at 3:35 PM
Blueprint Medicines Ayvakit Gets FDA Nod for Rare CancerBlueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
finance.yahoo.com - January 10 at 3:35 PM
UPDATE 2-FDA approves Blueprints stomach cancer therapy priced at $32,000 per monthUPDATE 2-FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month
www.cnbc.com - January 10 at 7:27 AM
FDA approves Cambridge biotechs first-ever drug for cancerFDA approves Cambridge biotech's first-ever drug for cancer
www.bizjournals.com - January 9 at 8:59 PM
FDA approves Cambridge biotech's first-ever drug for cancerFDA approves Cambridge biotech's first-ever drug for cancer
finance.yahoo.com - January 9 at 8:59 PM
U.S. FDA approves Blueprints therapy for rare type of stomach cancerU.S. FDA approves Blueprint's therapy for rare type of stomach cancer
www.nasdaq.com - January 9 at 3:59 PM
FDA OKs Blueprint kinase inhibitor for GI tumorFDA OKs Blueprint kinase inhibitor for GI tumor
seekingalpha.com - January 9 at 3:59 PM
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal TumorBlueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
finance.yahoo.com - January 9 at 3:59 PM
Blueprint Medicines initiates U.S. application for pralsetinibBlueprint Medicines initiates U.S. application for pralsetinib
seekingalpha.com - January 8 at 5:05 PM
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung CancerBlueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
finance.yahoo.com - January 8 at 5:05 PM
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular CarcinomaCStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
finance.yahoo.com - January 6 at 3:26 PM
Blueprint Medicines (BPMC) Up More Than 30% YTD: Heres WhyBlueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why
www.nasdaq.com - December 13 at 12:43 PM
Blueprints (BPMC) Systemic Mastocytosis Study Data ImpressesBlueprint's (BPMC) Systemic Mastocytosis Study Data Impresses
www.nasdaq.com - December 10 at 5:18 PM
Biotech accelerator teams with investment firm for $210M fund raiseBiotech accelerator teams with investment firm for $210M fund raise
finance.yahoo.com - December 10 at 7:16 AM
Notable Thursday Option Activity: ETSY, BPMC, ALNYNotable Thursday Option Activity: ETSY, BPMC, ALNY
www.nasdaq.com - December 5 at 5:18 PM
Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?
finance.yahoo.com - December 5 at 12:18 PM
Blueprint Medicines down 7% on bearish call at Deutsche BankBlueprint Medicines down 7% on bearish call at Deutsche Bank
seekingalpha.com - December 2 at 12:40 PM
Is Blueprint Medicines Corporations (NASDAQ:BPMC) CEO Being Overpaid?Is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Being Overpaid?
finance.yahoo.com - December 2 at 7:39 AM
Is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Being Overpaid?Is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Being Overpaid?
finance.yahoo.com - December 2 at 7:39 AM
Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - November 21 at 2:14 PM
Blueprint Medicines to Present at Jefferies 2019 London Healthcare ConferenceBlueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
finance.yahoo.com - November 14 at 2:19 PM
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What is a Tariff?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel